Skip to content
lsd.com
TerminatedPhase 4Results posted

The Effect of Ketamine on the Length of Hospital Stay of Patients Hospitalized With Suicidal Ideation.

NCT02997722 · Allen Richert

Closed to entry
Status
Not accepting participants
Phase 4
Phase
4
Target enrolment
1
Study sites
1 US states

What it is testing

Summary

This study will evaluate the effect of ketamine on the treatment of patients hospitalized with suicidal thoughts. Half of the patients will receive one dose of ketamine in the vein. The other half will receive a placebo. Because we think that ketamine will improve depression and suicidal thoughts, we expect that patients who receive ketamine will require less time in the hospital than patients who receive placebo.

Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.

What counts as success

Primary outcome measures

  • Inpatient Hospital Length of Stay

    Measured over The dates and times of each patients' admission to and discharge from the inpatient unit (i.e., the data necessary to calculate length of stay) were collected by chart review performed approximately 6 months after enrollment in the study.

A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.

Who can take part

Eligibility, as published

18 Years to 64 Years
Ages
All
Sex
Not accepted
Healthy volunteers
Inclusion Criteria: 1. Men and women between the ages of 18 and 64 2. Patients admitted to the University of Mississippi Medical Center inpatient psychiatry service with suicidal ideations Exclusion Criteria: 1. Lifetime history of schizophrenia or other primary psychotic disorder 2. Current psychotic or manic symptoms 3. Substance use disorder within one month of admission 4. Positive urine toxicology at admission 5. Any lifetime abuse of ketamine or phencyclidine 6. Systolic BP \>180 mmHg or diastolic BP \>110 mmHg 7. Any patient who has eaten food within 8 hours prior to receiving the ketamine infusion or who has drank clear liquids within 2 hours prior to receiving the infusion 8. Known central nervous system (CNS) mass 9. CNS abnormalities 10. Hydrocephalus 11. Glaucoma 12. Acute globe injury 13. Porphyria 14. Untreated thyroid disease 15. Known coronary artery disease with poor functional capacity 16. Pregnancy 17. Currently breast-feeding

Where

1 study site

FacilityCityRegionCountry
University of Mississippi Medical CenterJacksonMississippiUnited States

On the registry

Contact the trial directly

This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.

Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.

NCT02997722 on ClinicalTrials.gov →

Last updated in the registry 2020-06-02. Registry records change; this page reflects the data build of 2026-08-25.

Related

Where this trial sits

Substance

Recruiting in